Research Article

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol

Table 1

Clinical data and features.

Age (years)64.7 ± 10.8
Gender (men : women)27 : 24
HbA1c (%)7.8 ± 1.7
DM duration (years)8.6 ± 9.5
BCVA ( units before)0.39 ± 0.30
CMT (μm; before)489.6 ± 106.8
Injection times3.8 ± 2.4
SRD (SRD+ : SRD−)16 : 35
Pretreatment of
 IVR/IVB (eyes)27
 PC (eyes)34
 STTA (eyes)38
Additional treatmentSTTA 3, PC 5, PPV 1
Length from RPE to EZ line (μm)57.8 ± 10.0
Length from RPE to ELM line (μm)82.6 ± 6.3

BCVA, best-corrected visual acuity; CMT, central macular thickness; SRD, serous retinal detachment; IVR, intravitreal ranibizumab injection; IVB, intravitreal bevacizumab injection; PC, photocoagulation; STTA, sub-Tenon’s capsule triamcinolone acetonide; RPE, retinal pigment epithelium; EZ, ellipsoid zone; ELM, external limiting membrane.